AnaCardio Raises €62.5M in Series B Funding
AnaCardio, a Swedish clinical-stage biopharmaceutical company, has raised €62.5 million in Series B funding to advance its heart failure drug programs.
Topic
Heart Failure
Topic
Topic
Topic
AnaCardio, a Swedish clinical-stage biopharmaceutical company, has raised €62.5 million in Series B funding to advance its heart failure drug programs.